Jimmy Joe
2 years ago
jbdiver still waiting for the other shoe to drop~? Are you short something~?
Lannett an older company. Will truly be sorry to see it go. Hopefully someone comes in to buy them.
One company has nothing to do with the other. Management always rises to the top or sinks to the bottom.
In Pharmaceuticals, unlike other industries/sectors things metastasize at a much slower rate. NDAs, ANDAs, R&D all take years. Compliance is another issue and often times the people you surround your company with ensure success or failure.
Attracting the best talent for the company is another problem. AND experienced leadership is the KEY. Something many antsy investors miss.
All it takes is one missed opportunity, a compliance issue, or losing valued talent that kept the company viable for decades. An iconic company gone. Sincerely sorry to see Lannett this way.
JB Diver, I do wish you all the best. The lack of understanding is unreal. You and Ama need to form a book club.
NASDAQ2020
2 years ago
NYSE to Suspend Trading Immediately in Lannett Company, Inc. (LCI) and Commence Delisting Proceedings
April 19, 2023, 4:30 PM EDT
NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (โNYSEโ, the โExchangeโ) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Lannett Company, Inc. (the โCompanyโ) - ticker symbol LCI - from the NYSE. Trading in the Companyโs common stock will be suspended immediately.
NYSE Regulation reached its decision to delist the Companyโs common stock pursuant to Section 802.01B of the NYSEโs Listed Company Manual because the Company had fallen below the NYSEโs continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least $15,000,000.
The Company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange. The NYSE will apply to the Securities and Exchange Commission to delist the common stock upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staffโs decision.
sharkey1
2 years ago
I may have to lower my expectations for our fin's on nov.14
Three Months Ended
(In thousands)
September 30,
Medical Indication
2022
2021
Analgesic
$
3,424
$
5,314
Anti-Psychosis
2,620
3,715
Cardiovascular
10,882
14,100
Central Nervous System
20,794
22,785
Endocrinology
7,312
7,845
Gastrointestinal
7,942
15,240
Infectious Disease
5,069
12,515
Migraine
3,324
4,685
Respiratory/Allergy/Cough/Cold
1,202
3,114
Other
8,759
10,352
Contract manufacturing revenue
3,751
1,860
Total net sales
$
75,079
$
101,525